Abstract
Background & Aims Non-alcoholic fatty liver disease (NAFLD) is globally prevalent and confers a high risk of morbidity via progression to non-alcoholic steatohepatitis (NASH). Circadian disruption in mouse models contributes to the development of hepatic steatosis and inflammation, however evidence in humans is lacking. We investigated how shift working and chronotype were associated with NAFLD/NASH in UK Biobank participants.
Methods We stratified 282,303 UK Biobank participants into day, irregular-shift, and permanent night-shift workers. We compared the likelihood of NAFLD/NASH in these groups using: a) Dallas Steatosis Index (DSI), b) NAFLD/NASH ICD10 codes, and c) liver proton density fat fraction (PDFF) after serially adjusting for age, sex, ethnicity, sleep, alcohol, smoking, and body mass index. We further assessed the relationship of baseline chronotype with likelihood of NAFLD/NASH using the same outcomes and covariates.
Results Compared to day workers, irregular-shift workers were more likely to have NAFLD/NASH defined by high DSI (odds ratio (OR) 1.29 (95% CI 1.18–1.4)) after adjusting for all covariates excluding BMI, with some attenuation after additional adjustment for BMI (OR 1.12 (1.03-1.22)). Likelihood of DSI-defined NAFLD/NASH was also higher in permanent night-shift workers (OR 1.08 (0.9–1.29)) in the fully-adjusted model. Compared to participants with intermediate chronotype, those with extreme late chronotype had a higher likelihood of DSI-defined NAFLD/NASH (OR 1.45 (1.34–1.56)) and a higher likelihood of NAFLD/NASH by ICD10 code (OR 1.23 (1.09–1.39)). Liver PDFF was elevated in irregular shift workers, but not permanent night shift workers.
Conclusions Irregular-shift work and chronotype are associated with NAFLD/NASH, suggesting circadian misalignment as an underlying mechanism. These findings have implications for health interventions to mitigate the detrimental effect of shift work.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work is supported by an MRC programme grant MR/P023576/1. DWR is a Wellcome Investigator, Wellcome Trust (107849/Z/15/Z). TM is funded via a Wellcome Trust Clinical Research Training Fellowship (ref. 102176/B/13/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data are available at https://www.ukbiobank.ac.uk/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement: the authors declare no conflicts of interest
Financial support: The work is supported by an MRC programme grant MR/P023576/1. DWR is a Wellcome Investigator, Wellcome Trust (107849/Z/15/Z). TM is funded via a Wellcome Trust Clinical Research Training Fellowship (ref. 102176/B/13/Z).
Data Availability
All data produced in the present work are contained in the manuscript
